Update on diagnosis and treatment of mastocytosis

Current Allergy and Asthma Reports

Volumn 11, Issue 4, 2011, Pages 292-299

  Brockow, Knut ^a   Ring, Johannes ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Anaphylaxis; Diagnosis; KIT mutation; Mast cell activation syndrome; Mastocytosis; Prognosis; Therapy; Treatment

Indexed keywords

ADRENALIN; ANTIHISTAMINIC AGENT; CORTICOSTEROID; MASITINIB; MILTEFOSINE; PROTEIN KINASE C; STAT5 PROTEIN;

ANAPHYLAXIS; ARTICLE; BASOPHIL; BONE DENSITY; CELL INFILTRATION; CLINICAL FEATURE; CYTOREDUCTIVE SURGERY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; GENE; GENE ACTIVATION; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HOT FLUSH; HRAS GENE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; INSECT ALLERGY; KRAS GENE; MAST CELL; MASTOCYTOSIS; MOLECULAR DYNAMICS; MRAS GENE; NAUSEA; NRAS GENE; ONCOGENE C KIT; OSTEOPOROSIS; SIGNAL TRANSDUCTION; VOMITING;

ANAPHYLAXIS; GENE EXPRESSION PROFILING; HUMANS; MASTOCYTOSIS; MUTATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-KIT; SIGNAL TRANSDUCTION;

EID: 80052446526     PISSN: 15297322     EISSN: 15346315     Source Type: Journal    
DOI: 10.1007/s11882-011-0199-2     Document Type: Article

References (50)

1. Brockow K, Metcalfe DD. Mastocytosis. Chem Immunol Allergy. 2010;95:110-24.
2. Valent P, Akin C, Escribano L, et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest. 2007;37:435-53. (Pubitemid 46817344)
3. Brockow K, Jofer C, Behrendt H, Ring J. Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients. Allergy. 2008; 63:226-32. This article describes anaphylaxis in mastocytosis clinically.
4. Gonzalez de Olano D, de la Hoz Caballer B, Nunez Lopez R, et al. Prevalence of allergy and anaphylactic symptoms in 210 adult and pediatric patients with mastocytosis in Spain: a study of the Spanish network on mastocytosis (REMA). Clin Exp Allergy. 2007;37:1547-55. Prevalence of allergy and anaphylaxis is analysed in patients with mastocytosis. (Pubitemid 47460231)
5. Gonzalez-de-Olano D, Alvarez-Twose I, Morgado JM, et al. Evaluation of basophil activation in mastocytosis with hymenoptera venom anaphylaxis. Cytometry B Clin Cytom. 2010;Nov 10 (Epub ahead of print).
6. Bonadonna P, Perbellini O, Passalacqua G, et al. Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels. J Allergy Clin Immunol. 2009;123:680-6. This was the first paper to describe high frequency of clonal mast cell disease in insect venom anaphylaxis patients with increased tryptase levels.
7. Wagner N, Fritze D, Przybilla B, et al. Fatal anaphylactic sting reaction in a patient with mastocytosis. Int Arch Allergy Immunol. 2008;146:162-3. (Pubitemid 351685480)
8. Matito A, Bartolome-Zavala B, Alvarez-Twose I, et al. IgEmediated anaphylaxis to Hippobosca equina in a patient with systemic mastocytosis. Allergy. 2010;65:1058-9.
9. Goldfinger MM, Sandadi J. Undiagnosed systemic mastocytosis in a teenager revealed during general anesthesia. Paediatr Anaesth. 2010;20:290-1.
10. Bonadonna P, Zanotti R, Pagani M, et al. How much specific is the association between hymenoptera venom allergy and mastocytosis? Allergy. 2009;64:1379-82.
11. Pfeffer I, Fischer J, Biedermann T. Acetylsalicylic acid dependent anaphylaxis to carrots in a patient with mastocytosis. J Dtsch Dermatol Ges. 2011;9:230-1.
12. Ludolph-Hauser D, Rueff F, Fries C, et al. Constitutively raised serum concentrations of mast-cell tryptase and severe anaphylactic reactions to Hymenoptera stings. Lancet. 2001;357:361-2. (Pubitemid 32128546)
13. Rueff F, Przybilla B, Bilo MB, et al. Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase-a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity. J Allergy Clin Immunol. 2009;124:1047-54. This multicenter study confirmed basal tryptase levels as a major predictor of the severity of insect sting anaphylaxis.
14. Sokol H, Georgin-Lavialle S, Grandpeix-Guyodo C, et al. Gastrointestinal involvement and manifestations in systemic mastocytosis. Inflamm Bowel Dis. 2010;16:1247-53.
15. Manara M, Varenna M, Cantoni S, et al. Osteoporosis with vertebral fractures in young males, due to bone marrow mastocytosis: a report of two cases. Clin Exp Rheumatol. 2010;28:97-100.
16. Barete S, Assous N, de Gennes C, et al. Systemic mastocytosis and bone involvement in a cohort of 75 patients. Ann Rheum Dis. 2010;69:1838-41.
17. Madendag IC, Madendag Y, Tarhan I, et al. Mastocytosis in pregnancy. Taiwan J Obstet Gynecol. 2010;49:192-6.
18. Worobec AS, Akin C, Scott LM, Metcalfe DD. Mastocytosis complicating pregnancy. Obstet Gynecol. 2000;95:391-5. (Pubitemid 30100505)
19. Uzzaman A, Maric I, Noel P, et al. Pediatric-onset mastocytosis: a long term clinical follow-up and correlation with bone marrow histopathology. Pediatr Blood Cancer. 2009;53:629-34.
20. Brockow K, Scott LM, Worobec AS, et al. Regression of urticaria pigmentosa in adult patients with systemic mastocytosis: correlation with clinical patterns of disease. Arch Dermatol. 2002;138:785-90. (Pubitemid 34625523)
21. Escribano L, Alvarez-Twose I, Sanchez-Munoz L, et al. Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients. J Allergy Clin Immunol. 2009;124:514-21. Prognosis of mastocytosis is linked to the presence of the D816V c-kit mutation in multiple hematologic lineages.
22. Bodemer C, Hermine O, Palmerini F, et al. Pediatric mastocytosis is a clonal disease associated with D816V and other activating c- KIT mutations. J Invest Dermatol. 2010;130:804-15.
23. Yang Y, Letard S, Borge L, et al. Pediatric mastocytosis-associated KIT extracellular domain mutations exhibit different functional and signaling properties compared with KIT-phosphotransferase domain mutations. Blood. 2010;116:1114-23.
24. Chaix A, Lopez S, Voisset E, et al. Mechanisms of STAT protein activation by oncogenic kit mutants in neoplastic mast cells. J Biol Chem. 2011;286:5956-66.
25. Baumgartner C, Cerny-Reiterer S, Sonneck K, et al. Expression of activated STAT5 in neoplastic mast cells in systemic mastocytosis: subcellular distribution and role of the transforming oncoprotein KIT D816V. Am J Pathol. 2009;175:2416-29.
26. Niedoszytko M, Bruinenberg M, Van Doormaal JJ, et al. Gene expression analysis predicts insect venom anaphylaxis in indolent systemic mastocytosis. Allergy. 2010;Dec 8 (Epub ahead of print).
27. Niedoszytko M. Oude Elberink JN, Bruinenberg M et al. Gene expression profile, pathways, and transcriptional system regulation in indolent systemic mastocytosis. Allergy. 2011;66:229-37.
28. Wilson TM, Maric I, Simakova O, et al. Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis. Haematologica. 2011;96:459-63.
29. Pardanani A, Tefferi A. Proposal for a revised classification of systemic mastocytosis. Blood. 2010;115:2720-1.
30. Valent P, Akin C, Sperr WR, et al. Refinements in response criteria in systemic mastocytosis: reply to a proposal. Eur J Haematol. 2010;116:850-1.
31. Butterfield JH. Increased leukotriene E4 excretion in systemic mastocytosis. Prostaglandins Other Lipid Mediat. 2010;92:73-6.
32. Akin C, Scott LM, Kocabas CN, et al. Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with "idiopathic" anaphylaxis. Blood. 2007;110:2331-3. Idiopathic anaphylaxis may be associated with clonal mast cell disease. (Pubitemid 47523152)
33. Akin C, Valent P, Metcalfe DD. Mast cell activation syndrome: proposed diagnostic criteria. J Allergy Clin Immunol. 2010;126:1099-104.
34. Alvarez-Twose I, Gonzalez de Olano D, Sanchez-Munoz L, et al. Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms. J Allergy Clin Immunol. 2010;125:1269-78. Patients with fragments or signs of anaphylaxis differ clinically depending on the absence or presence of clonal mast cell disease. This information can be used to decide whether a bone marrow biopsy should be performed for the exclusion of mastocytosis.
35. Zanotti R, Bonadonna P, Bonifacio M, et al. Isolated bone marrow mastocytosis: an underestimated subvariant of indolent systemic mastocytosis. Haematologica. 2011;96:482-4.
36. Teodosio C, Garcia-Montero AC, Jara-Acevedo M, et al. Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes. J Allergy Clin Immunol. 2010;125:719-26.
37. Brockow K, Grosber M, Hölzle K, et al. Neues zur Therapie der Mastozytose. Aktuelle Dermatol. 2009;12:491-5.
38. Carter MC, Uzzaman A, Scott LM, et al. Pediatric mastocytosis: routine anesthetic management for a complex disease. Anesth Analg. 2008;107:422-7.
39. Gonzalez de Olano D, Alvarez-Twose I, Esteban-Lopez MI, et al. Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with Hymenoptera venom anaphylaxis. J Allergy Clin Immunol. 2008;121:519-26.
40. Kontou-Fili K, Filis CI, Voulgari C, Panayiotidis PG. Omalizumab monotherapy for bee sting and unprovoked "anaphylaxis" in a patient with systemic mastocytosis and undetectable specific IgE. Ann Allergy Asthma Immunol. 2010;104:537-9.
41. Pitt TJ, Cisneros N, Kalicinsky C, Becker AB. Successful treatment of idiopathic anaphylaxis in an adolescent. J Allergy Clin Immunol. 2010;126:415-6.
42. Hadzijusufovic E, Peter B, Gleixner KV, et al. H1-receptor antagonists terfenadine and loratadine inhibit spontaneous growth of neoplastic mast cells. Exp Hematol. 2010;38:896-907.
43. Edwards AM, Hagberg H. Oral and inhaled sodium cromoglicate in the management of systemic mastocytosis: a case report. J Med Case Rep. 2010;4:193.
44. Vieira Dos Santos R, Magerl M, Martus P, et al. Topical sodium cromoglicate relieves allergen- and histamine-induced dermal pruritus. Br J Dermatol. 2010;162:674-6.
45. Hartmann K, Siebenhaar F, Belloni B, et al. Effects of topical treatment with the raft modulator miltefosine and clobetasol in cutaneous mastocytosis: a randomized, double-blind, placebocontrolled trial. Br J Dermatol. 2010;162:185-90.
46. Prignano F, Troiano M, Lotti T. Cutaneous mastocytosis: successful treatment with narrowband ultraviolet B phototherapy. Clin Exp Dermatol. 2010;35:914-5.
47. Sotiriou E, Apalla Z, Ioannides D. Telangiectasia macularis eruptive perstans successfully treated with PUVA therapy. Photodermatol Photoimmunol Photomed. 2010;26:46-7.
48. Heide R, de Waard-van der Spek FB R, den den Hollander JC, et al. Efficacy of 25% diluted fluticasone propionate 0.05% cream as wet-wrap treatment in cutaneous mastocytosis. Dermatology. 2007;214:333-5. (Pubitemid 46659017)
49. Lim KH, Pardanani A, Butterfield JH, et al. Cytoreductive therapy in 108 adults with systemic mastocytosis: outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine. Am J Hematol. 2009;84:790-4.
50. MetcalfeDD.Mast cells andmastocytosis. Blood. 2008;112:946-56.